Cencora (COR) Aandelenoverzicht
Cencora, Inc. koopt en distribueert farmaceutische producten in de Verenigde Staten en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 5/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 4/6 |
Beloningen
Risicoanalyse
COR Community Fair Values
Create NarrativeSee what 51 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cencora, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$308.78 |
| 52 Week Hoogtepunt | US$377.54 |
| 52 Week Laag | US$244.82 |
| Bèta | 0.57 |
| 1 maand verandering | -2.91% |
| 3 maanden verandering | 9.85% |
| 1 Jaar Verandering | 6.92% |
| 3 jaar verandering | 64.93% |
| 5 jaar verandering | 151.80% |
| Verandering sinds IPO | 10,356.04% |
Recent nieuws en updates
COR: Fair View Will Weigh Therapy Enablement Push And Nucleus Pilot Outcomes
Analysts now cite a $10 rise in their Cencora price target to $330, reflecting updated views on fair value, discount rate, revenue growth assumptions and profit margin outlooks, while still applying a similar future P/E framework. What’s in the News for Cencora Cencora’s Accelerate Pharmacy Solutions unit launched a Cell and Gene Therapy Enablement service that is designed to help health systems build and scale cell and gene therapy programs, with tailored support around financial confidence, operational readiness and scalable growth.
COR: Expanded Buybacks And Higher 2026 EPS Guidance Will Support Long-Term Upside
Analysts have adjusted their price target for Cencora to $372.58 from $350.58, citing updated assumptions for discount rates, profit margins, and future P/E multiples in their valuation work. What's in the News for Cencora Cencora reported a strong fiscal third quarter with revenue growth and higher adjusted diluted EPS, and raised its 2026 adjusted EPS guidance range.Recent updates
COR: Fair View Will Weigh Therapy Enablement Push And Nucleus Pilot Outcomes
Analysts now cite a $10 rise in their Cencora price target to $330, reflecting updated views on fair value, discount rate, revenue growth assumptions and profit margin outlooks, while still applying a similar future P/E framework. What’s in the News for Cencora Cencora’s Accelerate Pharmacy Solutions unit launched a Cell and Gene Therapy Enablement service that is designed to help health systems build and scale cell and gene therapy programs, with tailored support around financial confidence, operational readiness and scalable growth.COR: Expanded Buybacks And Higher 2026 EPS Guidance Will Support Long-Term Upside
Analysts have adjusted their price target for Cencora to $372.58 from $350.58, citing updated assumptions for discount rates, profit margins, and future P/E multiples in their valuation work. What's in the News for Cencora Cencora reported a strong fiscal third quarter with revenue growth and higher adjusted diluted EPS, and raised its 2026 adjusted EPS guidance range.COR: Fair View Will Weigh Nucleus Rollout, Cell Therapy And Legal Risk
Analysts now cite slightly firmer revenue growth, profit margin assumptions and a higher future P/E, which together support a refreshed Cencora fair value estimate increasing from $310 to $320. What’s in the News for Cencora Cencora launched a multi site pilot of its enhanced Nucleus inventory management solution for specialty physician practices, combining updated hardware and software to support medication workflow efficiency, visibility and control.Cencora: Specialty Infrastructure Is Rewriting The Distributor Model
Summary Cencora (COR) is transitioning from a bulk pharmaceutical distributor to a specialty medicines infrastructure provider, targeting higher-margin, service-driven growth. Recent acquisitions of OneOncology and Retina Consultants of America are driving margin expansion, with Q2 adjusted gross profit up 15.7% and margin rising to 4.31%. Management raised FY2026 adjusted EPS guidance to $17.70–$17.90, expects $3B adjusted FCF, and targets 10–14% long-term EPS growth. Execution risks include integration of acquisitions, increased leverage, regulatory scrutiny, and high customer concentration, but specialty platform buildout is expected to deepen margins and retention. Read the full article on Seeking AlphaCOR: Fair Value View Will Weigh Nucleus Rollout And Cell Therapy Partnership
Analysts have raised their Cencora price target from $288.21 to $310.00, reflecting updated views on fair value, revenue, profit margins, and future P/E assumptions. What’s in the News for Cencora Cencora announced a multi-site pilot of its enhanced Nucleus inventory management solution for specialty physician practices, with deployment planned in phases across more than 20 practice sites.COR: Insider Buying And Fair Value View Will Shape Upcoming Share Performance
Analysts have nudged their price target for Cencora higher from $280.00 to about $288.21, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins, and future price-to-earnings (P/E) expectations. What’s in the News for Cencora Cencora stock moved 3.6% higher on June 23, 2026, alongside commentary that the shares are viewed as modestly undervalued relative to one intrinsic value estimate and supported by what sources describe as solid business fundamentals.Cencora (COR) Stock Could Be 20% Below Fair Value On Margin Growth Narrative
Cencora (COR) stock has drawn investor attention after recent trading performance, with the share price closing at $281.43. The move comes alongside mixed short term returns and a longer multi year track record. See our latest analysis for Cencora. Recent trading puts Cencora’s 30 day share price return at 9.20%, yet the stock is still down 16.95% year to date. Longer term total shareholder returns over three and five years remain positive, suggesting recent momentum is rebuilding after a...COR: Buybacks And New CFO Appointment Will Support Long Term Upside
Analysts have modestly reduced their price target on Cencora to $350.58 from $356.83. This reflects slightly updated views on fair value and future P/E assumptions.COR: Buybacks And New CFO Will Support Long Term Upside
Analysts now estimate Cencora's fair value at $356.83 per share, down from $373.08. This change reflects updated assumptions around slightly slower revenue growth, a modestly lower profit margin outlook, and a small shift in future P/E expectations.Specialty And AI Investments Will Shape A Stable Yet Constrained Future Trajectory
Catalysts About Cencora Cencora is a pharmaceutical services company that supports manufacturers, health systems, physician practices and pharmacies across the global pharmaceutical supply chain. What are the underlying business or industry changes driving this perspective?COR: Share Repurchases And CFO Transition Will Support Long Term Upside
Analysts now estimate Cencora’s fair value at about $373, down from roughly $403. This reflects slightly higher assumed discount rates and a lower future P/E multiple, partly offset by a marginally stronger profit margin profile in their updated models.COR: CFO Transition And Disciplined Buybacks Will Support Long-Term Upside
Analysts have trimmed their price target on Cencora by about $5 to reflect slightly updated assumptions around fair value, revenue growth, profit margins, and future P/E, while still viewing the shares through a similar overall framework. What's in the News Cencora plans a leadership change, with long serving Chief Financial Officer James F.COR: Rare Disease Collaborations And Distribution Reach Will Support Long-Term Upside
Analysts have kept their price target for Cencora steady at $407.92, citing only very small tweaks to inputs like revenue growth, profit margin and future P/E assumptions, rather than any shift in their overall view of the business. What's in the News Cencora announced that Chief Financial Officer James F.COR: Rare Disease Partnerships Will Support Long-Term Upside For Capital Markets Access
Analysts have adjusted their fair value estimate for Cencora to about $408 from $410, reflecting small tweaks to assumptions around the discount rate, revenue growth, profit margin, and future P/E rather than a major shift in the story. What's in the News Cencora plans for Chief Financial Officer James F.COR: Capital Markets And Rare-Disease Services Will Support Long-Term Upside
Analysts now place Cencora's fair value at $410.00, up from $403.79. This change reflects small adjustments to revenue growth assumptions, profit margin expectations, and future P/E estimates in their models.COR: 3PL Expansion And M&A Options Will Shape Balanced Long-Term Upside
Analysts have nudged their price target for Cencora higher to about $404 from roughly $400, citing refreshed assumptions around revenue growth, profitability and a modestly higher future P/E multiple. What's in the News Cencora is expanding its third party logistics capabilities in the United States and Europe, including adding NextPharma Logistics across Germany, Austria and Switzerland and planning a new 3PL facility in Italy in 2026, alongside increased cold chain capacity across its European network (company announcement).Cencora (NYSE:COR) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Cencora, Inc.'s ( NYSE:COR ) recent earnings report didn't offer any surprises, with the shares unchanged over the last...COR: Buybacks And 3PL Expansion Will Support Long-Term Upside Potential
Analysts have nudged their projected fair value for Cencora to $399.80 from $396.80, citing updated assumptions around revenue growth, profit margins, the discount rate and a slightly lower future P/E multiple. What's in the News Cencora completed a share repurchase program totaling 4,895,419 shares, or 2.49% of shares, for US$1,118.1m under the buyback announced on May 1, 2024 (Buyback Tranche Update).COR: Global 3PL Expansion And Logistics Investments Will Support Long-Term Upside
Analysts have nudged their price target on Cencora higher to about US$397 from roughly US$388. This reflects refreshed assumptions on revenue growth, profit margins and future P/E levels in their models.COR: Global 3PL Buildout And Higher Dividend Will Support Long-Term Upside
Analysts have nudged their price target on Cencora higher to about $388, citing slightly lower modeled revenue growth, a modestly stronger profit margin, and a small uptick in assumed future P/E as key drivers of the updated view. What's in the News Cencora announced investments to expand its third party logistics capabilities in the United States and Europe, including broader specialty logistics services for pharmaceutical companies worldwide.COR: Global 3PL Expansion And Dividend Increases Will Offset Goodwill Impairment Risks
Analysts have slightly raised their price target on Cencora, increasing fair value by about 1.8 dollars per share as they factor in marginally stronger projected revenue growth, a modestly higher long term profit margin, and a steady future earnings multiple. What's in the News Cencora is making major investments to expand its third party logistics network, including a new 500,000 square foot 3PL facility in Texas by 2028 and a tripling of ultra low and cryogenic storage capacity in the United States, to support growing demand for specialty medicines such as cell and gene therapies (company announcement).COR: Automated Distribution Expansion And Margins Will Balance Storage And Dividend Risks
Analysts have modestly raised their price target for Cencora, increasing the estimated fair value by $2.71 to $384.79. This adjustment is based on slight improvements in profit margin expectations and valuation multiples.COR: Automated Expansion And Margin Gains Will Offset Ongoing Legal Risks
Analysts have raised their price target for Cencora, increasing the estimated fair value from $338.29 to $382.07. They cite strengthened profit margin expectations, even though there is a slightly higher discount rate and moderated revenue growth forecasts.COR: Ongoing Litigation Settlement And Buybacks Will Shape Healthcare Delivery Evolution
Analysts have raised their price target for Cencora by $5 to $338.29. They cite updated forecasts for slightly lower near-term revenue growth, but a stronger overall fair value assessment.Digital Infrastructure And Specialty Services Will Redefine Healthcare Delivery
With both Cencora’s net profit margin and consensus revenue growth forecasts holding steady, analysts have maintained their price target unchanged at $333.29. What's in the News Cencora completed the repurchase of 4,895,419 shares (2.49% of shares outstanding) for $1,118.1 million under its buyback program announced in May 2024; no shares were repurchased from April to June 2025.Rendement voor aandeelhouders
| COR | US Healthcare | US Markt | |
|---|---|---|---|
| 7D | -5.3% | -3.0% | -0.1% |
| 1Y | 6.9% | 15.8% | 11.9% |
Rendement versus industrie: COR presteerde slechter dan de US Healthcare -sector, die het afgelopen jaar een rendement van 15.8 % opleverde.
Rendement versus markt: COR presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 11.9 % opleverde.
Prijsvolatiliteit
| COR volatility | |
|---|---|
| COR Average Weekly Movement | 3.9% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: COR heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van COR is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1871 | 49,000 | Bob Mauch | www.cencora.com |
Cencora, Inc. koopt en distribueert farmaceutische producten in de Verenigde Staten en internationaal. Het segment Healthcare Solutions van het bedrijf Healthcare Solutions distribueert generieke en injecteerbare farmaceutische producten, vrij verkrijgbare gezondheidsproducten, benodigdheden en apparatuur voor de thuiszorg en aanverwante diensten aan ziekenhuizen en gezondheidszorgsystemen voor acute zorg, onafhankelijke en ketenapotheken, postorderapotheken, medische klinieken, apotheken voor langdurige zorg en alternatieve locaties en andere klanten; distribueert plasma en andere bloedproducten, vaccins en andere farmaceutische specialiteiten; levert diensten op het gebied van apotheekbeheer, personeel en andere adviesdiensten; software voor voorraadbeheer aan particuliere en institutionele zorgverleners; verpakkingsoplossingen voor institutionele en particuliere zorgverleners; ondersteuning bij klinische proeven, productkeuring en commercialisering; data-analyse, resultatenonderzoek en andere diensten voor biotechnologische en farmaceutische fabrikanten; farmaceutische producten, vaccins, parasietenbestrijdingsmiddelen, diagnostica, microvoederingrediënten en andere producten voor de markten voor gezelschapsdieren en productiedieren; verkoopafdelingsdiensten voor fabrikanten; en biedt andere diensten aan artsen die gespecialiseerd zijn in verschillende ziektetoestanden, zoals oncologie, en aan andere zorgverleners, waaronder ziekenhuizen en dialyseklinieken. Het segment International Healthcare Solutions biedt internationale farmaceutische groothandel en aanverwante diensten, en wereldwijde commercialisatiediensten; distribueert farmaceutische producten, andere gezondheidsproducten en aanverwante diensten naar apotheken, artsen, gezondheidscentra en ziekenhuizen; en biedt gespecialiseerde transport- en logistieke diensten voor de biofarmaceutische industrie.
Cencora, Inc. Samenvatting
| COR fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$58.92b |
| Inkomsten(TTM) | US$2.62b |
| Inkomsten(TTM) | US$332.77b |
Is COR overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| COR resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$332.77b |
| Kosten van inkomsten | US$319.59b |
| Brutowinst | US$13.18b |
| Overige uitgaven | US$10.56b |
| Inkomsten | US$2.62b |
Laatst gerapporteerde inkomsten
Jun 30, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 13.75 |
| Brutomarge | 3.96% |
| Nettowinstmarge | 0.79% |
| Schuld/Eigen Vermogen Verhouding | 361.9% |
Hoe presteerde COR op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/21 03:44 |
| Aandelenkoers aan het einde van de dag | 2026/09/18 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/09/30 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Cencora, Inc. wordt gevolgd door 31 analisten. 13 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| David Toung | Argus Research Company |
| Eric Coldwell | Baird |
| Glen Santangelo | Barclays |